Opioid detection in maternal and neonatal hair and meconium: Characterization of an at-risk population and implications to fetal toxicology

Therapeutic Drug Monitoring

Volumn 32, Issue 3, 2010, Pages 318-323

  Moller, Monique ^a,b   Karaskov, Tatyana ^a   Koren, Gideon ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alcohol; Drugs of abuse; Hair detection; Intrauterine exposure; Meconium; Opioid; Placental transfer

Indexed keywords

ALCOHOL; BENZODIAZEPINE DERIVATIVE; COCAINE; FATTY ACID ESTER; METHADONE; OPIATE; OXYCODONE;

CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FETOTOXICITY; HAIR ANALYSIS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MECONIUM; NEWBORN; OPIATE ADDICTION; PREDICTION; PRENATAL EXPOSURE; PRIORITY JOURNAL;

ANALGESICS, OPIOID; COCAINE; ETHANOL; FATTY ACIDS; FEMALE; FETAL ALCOHOL SYNDROME; FETUS; HAIR; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; MECONIUM; NARCOTICS; OXYCODONE; POPULATION GROUPS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 77952956215     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181dca48b     Document Type: Conference Paper

References (48)

1. Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008;11(Suppl):S133-153.
2. McCleane G, Smith HS. Opioids for persistent noncancer pain. Anesthesiol Clin. 2007;25:787-807, ii-vi.
3. Havens JR, Stoops WW, Leukefeld CG, et al. Prescription opiate misuse among rural stimulant users in a multistate community-based study. Am J Drug Alcohol Abuse. 2009;35:18-23.
4. Havens JR, Oser CB, Leukefeld CG. Increasing prevalence of prescription opiate misuse over time among rural probationers. J Opioid Manag. 2007; 3:107-111.
5. Peindl KS, Mannelli P, Wu LT, et al. Trends in nonheroin opioid abuse admissions: 1992-2004. J Opioid Manag. 2007;3:215-223.
6. Fischer B, Rehm J, Brissette S, et al. Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health. 2005;82:250-266.
7. Fischer B, Patra J, Cruz MF, et al. Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug Alcohol Rev. 2008;31:1-8.
8. Solbergsdottir E, Bjornsson G, Gudmundsson LS, et al. Validity of self-reports and drug use among young people seeking treatment for substance abuse or dependence. J Addict Dis. 2004;23:29-38.
9. Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97:1097-1102
10. Vinner E, Vignau J, Thibault D, et al. Hair analysis of opiates in mothers and newborns for evaluating opiate exposure during pregnancy. Forensic Sci Int. 2003;133:57-62.
11. Ostrea EM Jr, Knapp DK, Tannenbaum L, et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr. 2001;138:344-348.
12. Garland M, Abildskov KM, Kiu TW, et al. Placental transfer and fetal elimination of morphine-3-beta-glucuronide in the pregnant baboon. Drug Metab Dispos. 2008;36:1859-1868.
13. Nanovskaya T, Deshmukh S, Brooks M, et al. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther. 2002;300:26-33.
14. Gerdin E, Rane A, Lindberg B. Transplacental transfer of morphine in man. J Perinat Med. 1990;18:305-312.
15. Kandall SR, Doberczak TM, Jantunen M, et al. The methadone-maintained pregnancy. Clin Perinatol. 1999;26:173-183.
16. Finnegan LP. Effects of maternal opiate abuse on the newborn. Fe d Proc. 1985;44:2314-2317.
17. Finnegan LP, Connaughton JF Jr, Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2:141-158
18. Neonatal drug withdrawal. American Academy of Pediatrics Committee on Drugs. Pediatrics. 1998;101:1079-1088.
19. Johnson K, Gerada C, Greenough A. Substance misuse during pregnancy. Br J Psychiatry. 2003;183:187-189.
20. Fendrich M, Johnson TP, Wislar JS, et al. The utility of drug testing in epidemiological research: results from a general population survey. Addiction. 2004;99:197-208.
21. Musshoff F, Driever F, Lachenmeier K, et al. Results of hair analyses for drugs of abuse and comparison with self-reports and urine tests. Forensic Sci Int. 2006;156:118-123.
22. Fishbain DA, Cutler RB, Rosomoff HL, et al. Validity of self-reported drug use in chronic pain patients. Clin J Pain. 1999;15:184-191.
23. Vinner E, Vignau J, Thibault D, et al. Neonatal hair analysis contribution to establishing a gestational drug exposure profile and predicting a withdrawal syndrome. Ther Drug Monit. 2003;25:421-432.
24. Compton P. The role of urine toxicology in chronic opioid analgesic therapy. Pain Manag Nurs. 2007;8:166-172.
25. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta. 2006;370:17-49.
26. Akiyama M, Matsuo I, Shimizu H. Formation of cornified cell envelope in human hair follicle development. Br J Dermatol. 2002;146:968-976.
27. Bar-Oz B, Klein J, Karaskov T, et al. Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse. Arch Dis Child Fetal Neonatal Ed. 2003;88:F98-F100.
28. Koren G, Hutson J, Gareri J. Novel methods for the detection of drug and alcohol exposure during pregnancy: implications for maternal and child health. Clin Pharmacol Ther. 2008;83:631-634.
29. Bar-Oz B, Klein J, Karaskov T, et al. Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse. Arch Dis Child Fetal Neonatal Ed. 2003;88:F98-F100.
30. Hutson JR, Aleksa K, Pragst F, et al. Detection and quantification of fatty acid ethyl esters in meconium by headspace-solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:8-12.
31. Klein J, Karaskov T, Koren G. Clinical applications of hair testing for drugs of abuse-the Canadian experience. Forensic Sci Int. 2000;107:281-288.
32. Lewis D, Moore C, Morrissey P, et al. Determination of drug exposure using hair: application to child protective cases. Forensic Sci Int. 1997;84: 123-128.
33. Koren G, Chan D, Klein J, et al. Estimation of fetal exposure to drugs of abuse, environmental tobacco smoke, and ethanol. Ther Drug Monit.
34. Huestis MA, Choo RE. Drug abuse's smallest victims: in utero drug exposure. Forensic Sci Int. 2002;128:20-30.
35. Yawn BP, Thompson LR, Lupo VR, et al. Prenatal drug use in Minneapolis-St Paul, Minn. A 4-year trend. Arch Fam Med. 1994;3:520-527.
36. Pichini S, Puig C, Zuccaro P, et al. Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the 'Meconium Project.' Forensic Sci Int. 2005;153:59-65.
37. Garcia-Bournissen F, Rokach B, et al. Cocaine detection in maternal and neonatal hair: implications to fetal toxicology. Ther Drug Monit. 2007;29: 71-76. (Pubitemid 46279879)
38. Garcia-Bournissen F, Rokach B, Karaskov T, et al. Methamphetamine detection in maternal and neonatal hair: implications for fetal safety. Arch Dis Child Fetal Neonatal Ed. 2007;92:F351-F355. (Pubitemid 47436217)
39. Huestis MA, Choo RE. Drug abuse's smallest victims: in utero drug exposure. Forensic Sci Int. 2002;128:20-30.
40. Kulaga V, Pragst F, Fulga N, et al. Hair analysis of fatty acid ethyl esters in the detection of excessive drinking in the context of fetal alcohol spectrum disorders. Ther Drug Monit. 2009;31:261-266.
41. Vilamovska AM, Brown Taylor D, Bluthenthal RN. Adverse drinking-related consequences among lower income, racial, and ethnic minority drinkers: cross-sectional results. Alcohol Clin Exp Res. 2009;33:645-653.
42. Gomberg ES. Treatment for alcohol-related problems: special populations: research opportunities. Recent Dev Alcohol. 2003;16:313-333.
43. Curtis PA, McCullough C. The impact of alcohol and other drugs on the child welfare system. Child Welfare. 1993;72:533-542.
44. Freisthler B, Weiss RE. Using Bayesian space-time models to understand the substance use environment and risk for being referred to child protective services. Subst Use Misuse. 2008;43:239-251.
45. Stade B, Ungar WJ, Stevens B, et al. Cost of fetal alcohol spectrum disorder in Canada. Can Fam Physician. 2007;53:1303-1304.
46. Stade B, Ali A, Bennett D, et al. The burden of prenatal exposure to alcohol: revised measurement of cost. Can J Clin Pharmacol. 2009;16:e91-e102.
47. Garland M, Abildskov KM, Kiu TW, et al. The contribution of fetal metabolism to the disposition of morphine. Drug Metab Dispos. 2005;33: 68-76.
48. Mucklow JC. The fate of drugs in pregnancy. Clin Obstet Gynaecol. 1986; 13:161-175.